Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Income from Continuing Operations (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Income from Continuing Operations for 8 consecutive years, with 13483952.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 37.59% to 13483952.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 94841058.0 through Dec 2025, down 142.54% year-over-year, with the annual reading at 63979492.0 for FY2025, 15.11% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 13483952.0 at Outlook Therapeutics, up from 14847398.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 13483952.0 in Q4 2025, with the low at 46357206.0 in Q1 2025.